OncoMatch/Clinical Trials/NCT05518110
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
Is NCT05518110 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Trametinib and Hydroxychloroquine for pancreatic cancer.
Treatment: Trametinib · Hydroxychloroquine — This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: mek inhibitor
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L; hemoglobin ≥ 9 g/dL
Kidney function
serum creatinine ≤ 1.5 x ULN
Liver function
total bilirubin ≤ 1.5 × ULN, AST ≤ 2.5 × ULN, ALT ≤ 2.5 × ULN (or ≤ 5 × ULN with liver metastases)
Cardiac function
Severe left ventricular dysfunction (ejection fraction < 45%) excluded; QTcF > 500 msec excluded; known congenital or acquired QT prolongation excluded; uncorrected hypokalemia and/or hypomagnesemia excluded
Serum creatinine ≤ 1.5 x ULN. Total bilirubin ≤ 1.5 × ULN, AST ≤ 2.5 × ULN, ALT ≤ 2.5 × ULN (or ≤ 5 × ULN with liver metastases). ANC ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L; hemoglobin ≥ 9 g/dL. Severe left ventricular dysfunction as defined by ejection fraction < 45%. Screening corrected QT interval by Fridericia (QTcF) > 500 msec. Known congenital or documented acquired QT prolongation. Uncorrected hypokalemia and/or hypomagnesemia.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify